DermBiont
Drug Discovery
DermBiont valuation and funding history | Last updated: October 24, 2023 | 4 funding rounds
Current Valuation
N/A
As of October 24, 2023
Total Funding Raised
N/A
Across 4 rounds
Last Round
Later Stage VC (Series B)
$35.2M
Last Funding
Oct 2023
Funding date
Capital Efficiency
N/A
Valuation / Funding
Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones
| Date | Round | Amount | Post-Valuation | Growth |
|---|---|---|---|---|
| October 24, 2023 | Later Stage VC (Series B) | $35.2M | N/A | - |
| December 17, 2021 | Early Stage VC (Series A2) | $35.4M | N/A | - |
| October 29, 2020 | Early Stage VC (Series A2) | $7.2M | N/A | - |
| June 18, 2019 | Early Stage VC (Series A) | $8.8M | N/A | - |
Valuation Analysis
Current Valuation Metrics
DermBiont is currently valued at N/A as of October 24, 2023.
What is DermBiont Worth in 2026?
DermBiont is a leading private company in the Drug Discovery sector. Track DermBiont's valuation history, funding timeline, and implied market value from secondary transactions on Premier Alternatives.
How DermBiont Valuation is Determined
Private company valuations like DermBiont's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including revenue growth, market opportunity, competitive positioning, and investor sentiment.